Back

This programme is supported by Bayer Pharma AG in the form of an educational grant. The scientific programme has not been influenced in any way by its sponsor

16 April 2023 (14:30 - 14:30)
Organised by:
Congress Presentation Part of: The new frontier in oral anticoagulation: Factor XIa inhibitors Stroke Prevention EHRA Premium Access EHRA 2023

4 More presentations in this session

Presentation thumbnail
Non-vitamin K antagonist oral anticoagulants (NOACs) – Limitations and new opportunities
Professor J. Steffel (Zurich, CH)
Slides Video
Presentation thumbnail
Factor XI inhibition – are NOACs obsolete? Mechanistic and pharmacological insights
Doctor J. Weitz (Hamilton, CA)
Slides Video
Presentation thumbnail
Factor XI inhibition – the new paradigm for atrial fibrillation and stroke
Professor G. Lip (Liverpool, GB)
Slides Video
Presentation thumbnail
Factor XI inhibition – other indications: acute coronary syndrome, venous thromboembolism
Professor D. Capodanno (Catania, IT)
Slides Video

Access the full session

Session thumbnail
The new frontier in oral anticoagulation: Factor XIa inhibitors
Video

The Event

Event poster

EHRA 2023

16 April 2023 14:30 CET
You may be interested in
thumbnail
Congress Presentation
Guideline-based education on stroke prevention and rhythm control in atrial fibrillation: A survey in the STEEER-AF study
31 March 2025
thumbnail
Congress Presentation
The effectiveness of supportive management programs in caregivers of patients with heart failure: a systemartic review
15 June 2024
thumbnail
Congress Session
Molecular actions of GLP-1 agonists and incretins
29 August 2025
thumbnail
Congress Presentation
One year after the 2021 EHRA practical guide on NOACs: main points and new aspects.
3 April 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources